ArticleBMC pediatrics2025
Intraoperative dexmedetomidine for prevention of postoperative delirium in pediatric patients after orthopedic surgery: a single-center retrospective study.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo evaluate the effectiveness of intraoperative dexmedetomidine in preventing postoperative delirium (POD) in pediatric patients undergoing lower extremity orthopedic surgery.
methodsThis retrospective study included pediatric patients aged 3-12 years who underwent lower extremity orthopedic surgery and received single-shot caudal block combined with intravenous patient-controlled analgesia (IV-PCA) from January 2021 to December 2023. Patients were divided into two groups according to intraoperative adjuvant medication: dexmedetomidine (1 µg/kg) or sufentanil (0.1 µg/kg). Propensity score matching (PSM) was used to balance baseline characteristics. The primary outcome was the incidence of POD, assessed by the Pediatric Anesthesia Emergence Delirium (PAED) scale. Secondary outcomes included postoperative pain scores (r-FLACC scale) and adverse events.
resultsAfter PSM, 128 patients (64 pairs) were analyzed. The incidence of POD was significantly lower in the dexmedetomidine group compared to the sufentanil group (14.1% vs. 34.4%, p = 0.01). Multivariate logistic regression revealed that intraoperative dexmedetomidine was independently associated with a reduced risk of POD (OR = 0.29, 95% CI: 0.12-0.74, p < 0.01). Dexmedetomidine also resulted in lower r-FLACC pain scores in the PACU and during the first 6 h postoperatively (all p < 0.01). No significant differences in hemodynamic changes or adverse events were observed between the groups.
conclusionIntraoperative dexmedetomidine significantly reduces the incidence of POD and improves early postoperative pain control in pediatric patients undergoing lower extremity orthopedic surgery, without increasing adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.